Tags

Type your tag names separated by a space and hit enter

Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy.
Int J Mol Sci. 2022 Nov 22; 23(23)IJ

Abstract

Objective markers for the neurodegenerative disorder progressive supranuclear palsy (PSP) are needed to provide a timely diagnosis with greater certainty. Non-coding RNA (ncRNA), including microRNA, piwi-interacting RNA, and transfer RNA, are good candidate markers in other neurodegenerative diseases, but have not been investigated in PSP. Therefore, as proof of principle, we sought to identify whether they were dysregulated in matched serum and cerebrospinal fluid (CSF) samples of patients with PSP. Small RNA-seq was undertaken on serum and CSF samples from healthy controls (n = 20) and patients with PSP (n = 31) in two cohorts, with reverse transcription-quantitative PCR (RT-qPCR) to confirm their dysregulation. Using RT-qPCR, we found in serum significant down-regulation in hsa-miR-92a-3p, hsa-miR-626, hsa-piR-31068, and tRNA-ValCAC. In CSF, both hsa-let-7a-5p and hsa-piR-31068 showed significant up-regulation, consistent with their changes observed in the RNA-seq results. Interestingly, we saw no correlation in the expression of hsa-piR-31068 within our matched serum and CSF samples, suggesting there is no common dysregulatory mechanism between the two biofluids. While these changes were in a small cohort of samples, we have provided novel evidence that ncRNA in biofluids could be possible diagnostic biomarkers for PSP and further work will help to expand this potential.

Authors+Show Affiliations

School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Psychiatry, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.Department of Psychiatry, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Psychiatry and Psychotherapy, Charité, 10117 Berlin, Germany. Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University Munich, 81675 Munich, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Psychiatry and Psychotherapy, Charité, 10117 Berlin, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, University of Bonn, Bonn 53127, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, University of Bonn, Bonn 53127, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, Technische Universität Dresden, 01307 Dresden, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, Technische Universität Dresden, 01307 Dresden, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, Rostock University Medical Center, 18147 Rostock, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany.German Center for Neurodegenerative Diseases (DZNE), Germany. Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany.Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0QQ, UK. Medical Research Council Cognition and Brain Sciences Unit, Cambridge CB2 7EF, UK.Department of Neurology, Royal Gwent Hospital, Newport NP20 2UB, UK.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, Technische Universität München, 81377 Munich, Germany.Brighton and Sussex Medical School, Brighton BN1 9QG, UK.Brighton and Sussex Medical School, Brighton BN1 9QG, UK.Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.German Center for Neurodegenerative Diseases (DZNE), Germany. Department of Neurology, Technische Universität München, 81377 Munich, Germany.School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36498882

Citation

Simoes, Fabio A., et al. "Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy." International Journal of Molecular Sciences, vol. 23, no. 23, 2022.
Simoes FA, Joilin G, Peters O, et al. Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. Int J Mol Sci. 2022;23(23).
Simoes, F. A., Joilin, G., Peters, O., Schneider, L. S., Priller, J., Spruth, E. J., Vogt, I., Kimmich, O., Spottke, A., Hoffmann, D. C., Falkenburger, B., Brandt, M., Prudlo, J., Brockmann, K., Fries, F. L., Rowe, J. B., Church, A., Respondek, G., Newbury, S. F., ... Hafezparast, M. (2022). Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. International Journal of Molecular Sciences, 23(23). https://doi.org/10.3390/ijms232314554
Simoes FA, et al. Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. Int J Mol Sci. 2022 Nov 22;23(23) PubMed PMID: 36498882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. AU - Simoes,Fabio A, AU - Joilin,Greig, AU - Peters,Oliver, AU - Schneider,Luisa-Sophie, AU - Priller,Josef, AU - Spruth,Eike Jakob, AU - Vogt,Ina, AU - Kimmich,Okka, AU - Spottke,Annika, AU - Hoffmann,Daniel C, AU - Falkenburger,Björn, AU - Brandt,Moritz, AU - Prudlo,Johannes, AU - Brockmann,Kathrin, AU - Fries,Franca Laura, AU - Rowe,James B, AU - Church,Alistair, AU - Respondek,Gesine, AU - Newbury,Sarah F, AU - Leigh,P Nigel, AU - Morris,Huw R, AU - Höglinger,Günter U, AU - Hafezparast,Majid, Y1 - 2022/11/22/ PY - 2022/10/12/received PY - 2022/11/11/revised PY - 2022/11/14/accepted PY - 2022/12/11/entrez PY - 2022/12/12/pubmed PY - 2022/12/15/medline KW - PSP KW - RNA-seq KW - biomarker KW - non-coding RNA KW - progressive supranuclear palsy JF - International journal of molecular sciences JO - Int J Mol Sci VL - 23 IS - 23 N2 - Objective markers for the neurodegenerative disorder progressive supranuclear palsy (PSP) are needed to provide a timely diagnosis with greater certainty. Non-coding RNA (ncRNA), including microRNA, piwi-interacting RNA, and transfer RNA, are good candidate markers in other neurodegenerative diseases, but have not been investigated in PSP. Therefore, as proof of principle, we sought to identify whether they were dysregulated in matched serum and cerebrospinal fluid (CSF) samples of patients with PSP. Small RNA-seq was undertaken on serum and CSF samples from healthy controls (n = 20) and patients with PSP (n = 31) in two cohorts, with reverse transcription-quantitative PCR (RT-qPCR) to confirm their dysregulation. Using RT-qPCR, we found in serum significant down-regulation in hsa-miR-92a-3p, hsa-miR-626, hsa-piR-31068, and tRNA-ValCAC. In CSF, both hsa-let-7a-5p and hsa-piR-31068 showed significant up-regulation, consistent with their changes observed in the RNA-seq results. Interestingly, we saw no correlation in the expression of hsa-piR-31068 within our matched serum and CSF samples, suggesting there is no common dysregulatory mechanism between the two biofluids. While these changes were in a small cohort of samples, we have provided novel evidence that ncRNA in biofluids could be possible diagnostic biomarkers for PSP and further work will help to expand this potential. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/36498882/Potential_of_Non_Coding_RNA_as_Biomarkers_for_Progressive_Supranuclear_Palsy_ DB - PRIME DP - Unbound Medicine ER -